Benefits
Reduced osteoarthritis pain (meta-analysis evidence)
meta-analysis of 3 RCTs (n=287, median 3-month duration) found rosehip powder produced an effect size of 0.37 (95% CI 0.21-0.54) for pain reduction vs placebo. Number needed to treat = 6. Effect size is small-to-moderate but consistent across trials — comparable to other dietary supplements for OA pain (e.g., glucosamine).
Improved joint mobility
RCT showed rosehip powder significantly improved hip flexion (p<0.05) vs placebo over 4 months. Patient-reported global assessment of disease severity, pain on movement, and pain at rest all improved significantly.
Reduced NSAID consumption
Rein 2004 (n=100 OA patients, double-blind RCT) showed rosehip group had reduced consumption of analgesics and NSAIDs vs placebo. Patients reported improved general wellbeing alongside pain reduction.
Anti-inflammatory CRP reduction
Rosehip powder supplementation has been associated with reduction in C-reactive protein after 4 weeks of supplementation in OA patients. Combined with the in vitro anti-chemotactic effect on neutrophils and monocytes, this supports an anti-inflammatory mechanism rather than simple analgesia.
Mechanism of action
GOPO galactolipid anti-inflammatory action
GOPO — (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol — is the principal anti-inflammatory active. In vitro, GOPO inhibits chemotaxis of peripheral blood neutrophils and monocytes, reducing inflammatory cell infiltration into joint tissue. This is preserved only in cold-processed rosehip preparations; standard hot extraction destroys it.
Cytokine and matrix metalloproteinase suppression
GOPO reduces production of NO, PGE2, TNF-α, IL-1β, IL-6, and IL-12 by human blood cells. It also suppresses gene expression of matrix metalloproteinases, aggrecanases, TNF-α, and NF-κB — pathways central to cartilage degradation in osteoarthritis.
Antioxidant lipid composition
Rosehip provides ω-3 (α-linolenic acid) and ω-6 (linoleic acid) PUFAs, plus triterpenic acids (betulinic, oleanolic, ursolic acid), high vitamin C content (rosehip is a traditional vitamin C source), lycopene, and various polyphenols. Combined antioxidant capacity supports joint tissue against oxidative damage from inflammation.
Clinical trials
Random-effects meta-analysis using REML methods (Christensen, Bartels, Altman, Astrup, Bliddal 2008, Osteoarthritis Cartilage 16(9):965-972).
3 RCTs, total n=287 OA patients (145 rosehip, 142 placebo). Median trial duration 3 months. All 3 trials supported by manufacturer Hyben-Vital International.
Pooled effect size for pain reduction = 0.37 (95% CI 0.21-0.54). Number needed to treat = 6. Authors concluded rosehip powder produces a small-to-moderate but statistically significant pain reduction in OA patients vs placebo. Manufacturer-funding noted as a study limitation.
Randomized, double-blind, placebo-controlled crossover trial (Winther, Apel, Thamsborg 2005, Scand J Rheumatol 34(4):302-8).
94 patients with osteoarthritis of the hip or knee. Crossover design with rosehip powder 5 g/day vs placebo for 3 months each, with washout period.
Rosehip powder produced significant improvements vs placebo in WOMAC pain scores, joint stiffness, hip flexion, and patient-reported global assessment. 66% of patients reported reduction in pain on rosehip vs 35% on placebo. Established the foundational efficacy data and characteristic time-to-effect (~3 weeks).
Double-blind, placebo-controlled, randomized crossover trial (Rein, Kharazmi, Winther 2004, Phytomedicine 11(5):383-91).
100 OA patients receiving 5 g/day rosehip powder (Hyben Vital, standardized Rosa canina subspecies) vs placebo for 4 months in crossover design.
Rosehip powder significantly reduced pain (p<0.0078) and improved general wellbeing vs placebo. Reduced consumption of rescue analgesics and NSAIDs. Established that the standardized cold-processed Rosa canina subspecies (preserving GOPO galactolipid) produces clinically meaningful OA symptom relief.